NCT05131100 Korean Regulatory Post Marketing Surveillance for Somavert
| NCT ID | NCT05131100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pfizer |
| Condition | Acromegaly |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-07-13 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-07-13 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
Eligibility Criteria
Inclusion Criteria: All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible. Exclusion Criteria: Patients who are contraindicated for Somavert
Contact & Investigator
Pfizer CT.gov Call Center
STUDY DIRECTOR
Pfizer
Frequently Asked Questions
Who can join the NCT05131100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acromegaly. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05131100 currently recruiting?
Yes, NCT05131100 is actively recruiting participants. Contact the research team at ClinicalTrials.gov_Inquiries@pfizer.com for enrollment information.
Where is the NCT05131100 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05131100 clinical trial?
NCT05131100 is sponsored by Pfizer. The principal investigator is Pfizer CT.gov Call Center at Pfizer. The trial plans to enroll 100 participants.